Arylsulfatase B, Fibroblasts
Diagnosis of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request
Diagnostic testing for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Not recommended for carrier detection.
This test is not recommended for prenatal testing.
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
When this test is ordered, a fibroblast culture and cryopreservation for biochemical studies will always be performed at an additional charge. However, for multiple lysosomal enzyme assays on a patient utilizing fibroblast culture, only 1 culture is required regardless of the number of enzyme assays ordered. If viable cells are not obtained within 10 days, client will be notified.
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome) is an autosomal recessive lysosomal storage disorder caused by the deficiency of N-acetylgalactosamine 4-sulfatase, also known as arylsulfatase B (ARSB). The mucopolysaccharidoses are a group of disorders caused by the deficiency of any of the enzymes involved in the stepwise degradation of complex macromolecules called glycosaminoglycans (GAGs) including dermatan sulfate, heparan sulfate, keratan sulfate, and chondroitin sulfate. Accumulation of GAGs (also called mucopolysaccharides) in lysosomes interferes with normal functioning of cells, tissues, and organs.
Clinical features and severity of symptoms are widely variable, but typically include short stature, dysostosis multiplex, facial dysmorphism, stiff joints, hepatosplenomegaly, corneal clouding, and cardiac disease. Intelligence is usually normal. Rapidly progressing forms have an early onset of symptoms, significantly elevated GAGs, and can lead to death before the second or third decades. A more slowly progressing form has a later onset, milder skeletal manifestations, smaller elevations of GAGs, and typically a longer lifespan. Estimates of the incidence of MPS VI range from 1 in 250,000 to 1 in 300,000. Treatment options include hematopoietic stem cell transplantation and/or enzyme replacement therapy.
A diagnostic workup in an individual with MPS VI typically demonstrates elevated levels of urinary GAGs and increased dermatan sulfate detected on thin-layer chromatography. Reduced or absent activity of ARSB in leukocytes and/or fibroblasts is suggestive of a diagnosis of MPS VI. Sequencing of the ARSB gene allows for detection of disease-causing mutations in affected patients and identification of familial mutations allows for testing of at-risk family members (MPS6Z / Mucopolysaccharidosis VI, Full Gene Analysis). Currently, no clear genotype-phenotype correlations have been established.
ARSB activity is also reduced in 2 other rare autosomal recessive disorders, multiple sulfatase deficiency (MSD) and mucolipidosis II (I-cell disease). Both of these conditions present with developmental delays that make them clinically different from MPS VI. The symptoms of MSD mimic metachromatic leukodystrophy (MLD) as well as the mucopolysaccharidoses and can include developmental delay, neurologic regression, dysmorphic facies, dysostosis multiplex, organomegaly, ichthyosis, and chondroplasia punctata. If MSD is suspected, testing of an additional sulfatase enzyme, such as arylsulfatase A in MLD, can help determine if multiple sulfatases are deficient. I-cell disease is characterized by congenital or early infantile manifestations including coarse facial features, short stature, skeletal anomalies, cardio- and hepatomegaly, and developmental delays. This is a progressive disorder and death typically occurs in the first decade of life. Additional testing including hydrolase enzymes in serum, such as hexosaminidase A in Tay-Sach disease, is recommended if a diagnosis of I-cell is suspected.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
> or =6.08 nmol/min/mg protein
Arylsulfatase B is deficient in mucopolysaccharidosis VI, multiple sulfatase deficiency, and mucolipidosis II.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This test is not recommended for carrier testing for mucopolysaccharidosis VI (MPS VI).
Multiple sulfatase deficiency and mucolipidosis II may have reduced levels of arylsulfatase B; however, the enzyme activity may not be as significantly decreased as in MPS VI.
Interfering factors in diagnosing MPS VI, multiple sulfatase deficiency, or mucolipidosis II include lack of viable cells, bacterial contamination, failure to transport tissue in an appropriate media, excessive transport time, or exposure of the specimen to temperature extremes (freezing or >30 degrees C).
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S: Mucopolysaccharidosis VI. Orphanet J Rare Dis 2010 Apr 12;5:5
2. Neufeld EF, Muenzer J: Chapter 136: In The Metabolic Basis of Inherited Disease. Eighth edition. Edited by D Valle. AL Beaudet, B Vogelstein. New York, McGraw-Hill Book Company. Accessed 04/07/2017. Available at www.ommbid.com
3. Enns GM, Steiner RD, Cowan TM: Lysosomal disorders. In Pediatric Endocrinology and Inborn Errors of Metabolism. Edited by K Sarafoglou, GF Hoffmann, KS Roth. New York, McGraw-Hill Medical Division, 2009, pp 733-735
4. Wood T, Bodamer OA, Burin MG et al: Expert recommendations for the laboratory diagnosis of MPS VI. Mol Genet Metab 2012;106(1):73-82